# Advances in Cancer Immunotherapy

> **NIH NIH R13** · KEYSTONE SYMPOSIA · 2020 · $5,000

## Abstract

ABSTRACT
Support is requested for a Keystone Symposia conference entitled Advances in Cancer Immunotherapy,
organized by Drs. Antoni Ribas, W. Nicholas Haining and Priti Hegde. The conference will be held in Whistler,
British Columbia Canada from March 22-26, 2020.
Cancer immunotherapy by blocking immune inhibitory checkpoints or engineering T cells for adoptive cell
transfer is providing an unprecedented level of long-term antitumor activity in patients with several metastatic
cancers. However, the majority of patients with advanced cancers still do not experience sustained clinical
benefit from immunotherapy. Understanding the mechanistic basis of response and resistance to these
therapies and how therapeutic approaches could best be combined will be essential to continue progress. The
largest human experiment is currently being conducted with over 1,000 agents and combinations.
Understanding the results to date and determining what is working and what combinations are not working will
be important to refine our understanding of immunity in patients with cancer. Questions that remain
unanswered include: What is the rationale for the multiple immuno-oncology (IO) combinations being tested in
the clinic, how do cancers adapt and resist T cell attack, and can we better understand the tumor
microenvironment, thus paving the way for new approaches to cancer therapy. New analyses of patient-
derived samples provide information on adaptive and genetic resistance mechanisms to immunotherapy. The
conference program will include sessions which cover topics such as new analysis techniques, methodologies,
and how to integrate high throughput data to provide a more comprehensive understanding of cancer and the
immune system. Participants will leave the conference with an understanding of how the advancement of
cancer biology will be influenced by a better comprehension of tumor immunology.

## Key facts

- **NIH application ID:** 9910987
- **Project number:** 1R13CA246936-01
- **Recipient organization:** KEYSTONE SYMPOSIA
- **Principal Investigator:** Thale Cross Jarvis
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $5,000
- **Award type:** 1
- **Project period:** 2020-07-01 → 2021-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9910987

## Citation

> US National Institutes of Health, RePORTER application 9910987, Advances in Cancer Immunotherapy (1R13CA246936-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9910987. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*